SCHEMBL2914696

SCHEMBL2914696

CCN(CC)S(=O)(=O)c1ccc(O)cc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.70
LMNA P02545 4/20 0.70
SMN1; SMN2 Q16637 4/20 0.70
ESR1 P03372 4/20 0.65
NPC1 O15118 1/20 0.63
RAB9A P51151 1/20 0.63
SERPINE1 P05121 1/20 0.56
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KDM1A O60341 1/20 0.53
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
ALDH1A1 P00352 3/20 0.52
TSHR P16473 1/20 0.52
MAPT P10636 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MAPK1 P28482 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13286927 0.92 SERPINE1 (0.67) HTTLMNASMN1; SMN2ESR1NPC1
SCHEMBL11652623 0.82 SERPINE1 (0.55) HTTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL23057256 0.81 LMNA (0.73) HTTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL5023540 0.81 HTT (0.73) HTTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL10592845 0.81 LMNA (0.73) HTTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL5024746 0.79 LMNA (0.70) HTTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL2932439 0.79 LMNA (0.70) HTTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL4069104 0.79 LMNA (0.70) HTTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL23043651 0.79 LMNA (0.70) HTTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL3265384 0.79 LMNA (0.70) HTTLMNASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222160-B1 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR PHARMAXIS LTD (AU) 2015-03-18 EP disclosed
US-8426587-B2 Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor PHARMAXIS LTD. (AU) 2013-04-23 US disclosed
CN-101917845-A Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor PHARMAXIS LTD 2010-12-15 CN disclosed
US-20100298330-A1 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR PHARMAXIS LTD. (AU) 2010-11-25 US disclosed
EP-2222160-A2 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR Pharmaxis Ltd. (AU) 2010-09-01 EP disclosed
WO-2009066152-A2 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR PHARMAXIS LTD. (US) 2009-05-28 WO disclosed
EP-0343604-A2 Method of forming color images Fuji Photo Film Co., Ltd. (JP) 1989-11-29 EP disclosed
US-4505929-A Sulfur-substituted diphenyl ethers having antiviral activity THE DOW CHEMICAL COMPANY (US) 1985-03-19 US disclosed
EP-0034263-B1 SUBSTITUTED BENZONITRILES AND COMPOSITIONS FOR INHIBITING VIRUSES THE DOW CHEMICAL COMPANY (US) 1984-09-26 EP disclosed
US-4349568-A Sulfur-substituted diphenyl ethers having antiviral activity THE DOW CHEMICAL COMPANY (US) 1982-09-14 US disclosed
US-4332820-A ESPECIALLY EFFECTIVE AGAINST PICORNOVIRUSES THE DOW CHEMICAL COMPANY (US) 1982-06-01 US disclosed
EP-0034263-A2 Substituted benzonitriles and compositions for inhibiting viruses THE DOW CHEMICAL COMPANY (US) 1981-08-26 EP disclosed
US-4254144-A Substituted benzonitriles having antiviral activity THE DOW CHEMICAL COMPANY (US) 1981-03-03 US disclosed
US-4074059-A HERBICIDES AMERICAN CYANAMID COMPANY (US) 1978-02-14 US disclosed
US-3979203-A Sulfonamido herbicidal compositions and plant control methods using the same AMERICAN CYANAMID COMPANY (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298330-A1 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR VAPA, SLC6A11, VAPB HTT 471/4885LMNA 954/4885SMN1; SMN2 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.